Literature DB >> 25869587

In-Hospital Morbidity and Mortality Following Total Joint Arthroplasty in Patients with Hemoglobinopathies.

Mohammad Ali Enayatollahi1, Thomas A Novack1, Mitchell G Maltenfort1, Reza Mostafavi Tabatabaee1, Antonia F Chen1, Javad Parvizi1.   

Abstract

Given the growing patient population with hemoglobinopathies needing total joint arthroplasty (TJA) and paucity of literature addressing this cohort, we examined the in-hospital complications in patients with hemoglobinopathies undergoing TJA. International Classification of Diseases, Ninth Revision codes were used to search the Nationwide Inpatient Sample database for hemoglobinopathy patients undergoing primary or revision TJA. Hemoglobinopathy patients had a significant increase in cardiac, respiratory, and wound complications; blood product transfusion; pulmonary embolism; surgical site infection; and systemic infection events, while there was no significant effect on deaths, deep vein thrombosis, and renal complications. It may be prudent to implement blood conservation strategies as well as diligent postoperative protocols to minimize the need for transfusion and related complications in this patient population.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  blood conservation; complications; hemoglobinopathy; mortality; total joint replacement

Mesh:

Year:  2015        PMID: 25869587     DOI: 10.1016/j.arth.2015.03.031

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  2 in total

1.  What Is the Timing of General Health Adverse Events That Occur After Total Joint Arthroplasty?

Authors:  Daniel D Bohl; Nathaniel T Ondeck; Bryce A Basques; Brett R Levine; Jonathan N Grauer
Journal:  Clin Orthop Relat Res       Date:  2017-12       Impact factor: 4.176

Review 2.  Osteonecrosis in sickle cell disease: an update on risk factors, diagnosis, and management.

Authors:  Oyebimpe O Adesina; Lynne D Neumayr
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.